Farmacosmo Stock: price and insider trades · Italy

Every trade that managers of Farmacosmo disclose to Consob is tracked on this page. The company sits in the Health Care sector. Between 18 October 2025 and 18 October 2026, 10 insiders published 13 filings.

Not one open-market sale was filed. On the buying side, 8 insiders reported 11 purchases totalling €515. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 7 board members and 1 senior executive. One trade stands out by size: a purchase of €140, disclosed on 14 October 2026, or 0.0008% of market capitalisation.

The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 14 October 2026, 3 days ago. The median gap between a trade and its publication by Consob is 6 days. Under the Market Abuse Regulation, managers have three business days to notify their trades.

With 13 filings in twelve months, the company is more active than the median of 3 filings across the 225 companies we follow on the same exchange. Our records for Farmacosmo go back to 2023, with 11 purchases and no sales on the open market in total.

Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by Consob. They describe what insiders did and are not a recommendation.